| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/17/2000 | WO2000007593A1 Remedies or preventives for intractable epilepsy |
| 02/17/2000 | WO2000007592A1 Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis |
| 02/17/2000 | WO2000007591A1 INDOLE sPLA2 INHIBITORS |
| 02/17/2000 | WO2000007590A1 INDOLE sPLA2 INHIBITORS |
| 02/17/2000 | WO2000007589A1 Use of lipoxygenase metabolite of arachidonic acid and its derivatives in capsaicin-channel agonist |
| 02/17/2000 | WO2000007588A1 Pharmaceutical composition for injection based on paracetamol |
| 02/17/2000 | WO2000007587A1 Composition and method for treating peyronie's disease and other sub-dermal plaque manifestation disorders |
| 02/17/2000 | WO2000007586A1 Method of rearing and feeds |
| 02/17/2000 | WO2000007585A1 Use of calix(n)arenes for treating fibrotic diseases |
| 02/17/2000 | WO2000007584A2 Method of reducing retinal ganglion cell degeneration |
| 02/17/2000 | WO2000007583A2 Treatment of addiction and addiction-related behavior |
| 02/17/2000 | WO2000007582A2 Use of thiazolidinedione derivatives for the treatment or prevention of cataracts |
| 02/17/2000 | WO2000007581A2 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid |
| 02/17/2000 | WO2000007580A2 Pharmaceutical compositions against autoimmune diseases |
| 02/17/2000 | WO2000007579A2 Use of cyclopentabenzofuran-derivatives for combating nf-$g(k)b-dependent diseases |
| 02/17/2000 | WO2000007578A2 Combination of active substances, especially for the prophylaxis and therapy of ischaemic organic lesions and reperfusion syndromes |
| 02/17/2000 | WO2000007577A2 Phosphatidylcholine as a medicament for the protection of mucosa |
| 02/17/2000 | WO2000007576A2 INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE |
| 02/17/2000 | WO2000007575A2 Methods and compositions for increasing insulin sensitivity |
| 02/17/2000 | WO2000007570A1 Pharmaceutical compositions comprising ibuprofen and domperidone |
| 02/17/2000 | WO2000007569A1 Compressed compositions comprising clarified xanthan gum |
| 02/17/2000 | WO2000007568A1 Method for making coated gabapentine or pregabaline particles |
| 02/17/2000 | WO2000007567A1 Medicinal aerosol formulations |
| 02/17/2000 | WO2000007566A1 A new analgesic, anti-inflammatory and wound healing agent |
| 02/17/2000 | WO2000007565A2 Methods of ophthalmic administration |
| 02/17/2000 | WO2000007558A1 Use of ectoine or ectoine derivatives in cosmetic formulations |
| 02/17/2000 | WO2000007544A2 Vitronectin receptor antagonists |
| 02/17/2000 | WO2000007542A2 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance p |
| 02/17/2000 | WO2000007541A2 Use of xanthine derivatives for treating erectile disorder |
| 02/17/2000 | WO2000007515A1 Improved method for targeted topical treatment of disease |
| 02/17/2000 | WO2000007465A1 Solution for resuscitating multicellular organism cells and method for resuscitating multicellular organism cells by using the same |
| 02/17/2000 | WO2000007459A1 Method for increasing milk production in lactating dairy cattle |
| 02/17/2000 | WO2000007446A1 Microbicidal active substances |
| 02/17/2000 | WO1999065942A8 Cyclic somatostatin analogs |
| 02/17/2000 | WO1999063947A3 Method of hiv and hpv prophylaxis |
| 02/17/2000 | WO1999063931A3 Peptidyl-prolyl cis-trans isomerase inhibitors and uses therefor |
| 02/17/2000 | WO1999060985A3 Compounds, compositions and methods for treating erectile dysfunction |
| 02/17/2000 | WO1999058126B1 Use of neomycin for treating angiogenesis-related diseases |
| 02/17/2000 | WO1999058116A3 Novel formulation containing paroxetine |
| 02/17/2000 | WO1999058113A3 Novel formulation containing paroxetine |
| 02/17/2000 | WO1999056784A3 Inprovements in gene therapy using compositions comprising a polynucleotide and a nuclease inhibitor or interleukin-10 |
| 02/17/2000 | WO1999055332A8 Medicinal compositions |
| 02/17/2000 | WO1999055316A8 Kinase obtained from leishmania |
| 02/17/2000 | WO1999054310A3 New substituted amides, their production and their use |
| 02/17/2000 | WO1999051604A3 Process for the production of purine derivatives |
| 02/17/2000 | WO1999050461A9 Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
| 02/17/2000 | WO1999044596A3 Glycine transport inhibitors |
| 02/17/2000 | WO1999020261A3 Use of antigunal agents for the topial treatment of fungus-induced mucositis |
| 02/17/2000 | WO1999015159A3 Methods for increasing apoe levels for the treatment of neurodegenerative disease |
| 02/17/2000 | WO1999000346A8 Synthesis of dihydrohonokiol compositions |
| 02/17/2000 | DE19836697A1 New substituted 4-amino-2-aryl-pyrimidines, are soluble guanylate cyclase activators useful e.g. for treating atherosclerosis, hypertension, angina pectoris, thrombosis, asthma or diabetes |
| 02/17/2000 | DE19836406A1 New S,S-dioxobenzisothiazolinyl-substituted 3-azabicyclo (3.2.0) heptane derivatives, useful e.g. as neuroleptics, antidepressants, hypnotics and sedatives |
| 02/17/2000 | DE19836404A1 New benzimidazolonyl-substituted 3-azabicyclo (3.2.0) heptane derivatives, useful e.g. as neuroleptics, antidepressants, hypnotics and sedatives |
| 02/17/2000 | DE19836044A1 New 2-(hetero)aryl-alkanoic acid derivatives, useful as mixed endothelin receptor antagonists, e.g. for treating cardiac insufficiency, restenosis, hypertension or prostate cancer |
| 02/17/2000 | DE19830105C1 Acridinderivate Acridine |
| 02/17/2000 | CA2383623A1 3-methylidenyl-2-indolinone modulators of protein kinase |
| 02/17/2000 | CA2348637A1 A new analgesic, anti-inflammatory and wound healing agent |
| 02/17/2000 | CA2343163A1 Composition and method of treating disease with extract of musaceas |
| 02/17/2000 | CA2340020A1 Use of camptothecin derivatives, with reduced gastrointestinal toxicity |
| 02/17/2000 | CA2339878A1 Use of calix(n)arenes for treating fibrotic diseases |
| 02/17/2000 | CA2339857A1 Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride |
| 02/17/2000 | CA2339773A1 Substituted oxazoles and thiazoles derivatives as hppar gamma and hppar alpha activators |
| 02/17/2000 | CA2339666A1 Vitronectin receptor antagonists |
| 02/17/2000 | CA2339659A1 Method for increasing milk production in lactating dairy cattle |
| 02/17/2000 | CA2339484A1 Pyridinones for the treatment of sexual dysfunction |
| 02/17/2000 | CA2339473A1 Nutrient and therapeutic compositions for the treatment of cancer |
| 02/17/2000 | CA2339416A1 Short oligonucleotides for the inhibition of vegf expression |
| 02/17/2000 | CA2339413A1 Method for treatment of invasive cells |
| 02/17/2000 | CA2339408A1 Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom |
| 02/17/2000 | CA2339368A1 Inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase |
| 02/17/2000 | CA2339363A1 Remedies or preventives for intractable epilepsy |
| 02/17/2000 | CA2339362A1 Tricyclic carboxamides |
| 02/17/2000 | CA2339352A1 N-acetylglycosaminyltransferase genes |
| 02/17/2000 | CA2339340A1 Antisense oligonucleotides for the inhibition of vegf expression |
| 02/17/2000 | CA2339231A1 Topical delivery systems for active agents |
| 02/17/2000 | CA2339194A1 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders |
| 02/17/2000 | CA2339187A1 Substituted imidazo¬1,2a|azines as selective inhibitors of cox-2 |
| 02/17/2000 | CA2339178A1 2'-o-aminoethyloxyethyl-modified oligonucleotides |
| 02/17/2000 | CA2339146A1 Use of a nk-1 receptor antagonist for treating or preventing abnormal bone resorption |
| 02/17/2000 | CA2339122A1 Novel bi- and tri-cyclic aza compounds and their uses |
| 02/17/2000 | CA2339018A1 Fsh mimetics for the treatment of infertility |
| 02/17/2000 | CA2339007A1 Crystalline forms of osanetant |
| 02/17/2000 | CA2339003A1 Composition and method for treating peyronie's disease and other sub-dermal plaque manifestation disorders |
| 02/17/2000 | CA2338944A1 Succinoylamino lactams as inhibitors of a.beta. protein production |
| 02/17/2000 | CA2338855A1 Indole spla2 inhibitors |
| 02/17/2000 | CA2338727A1 Indole spla2 inhibitors |
| 02/17/2000 | CA2338594A1 Imidazoles and related compounds as .alpha.1a agonists |
| 02/17/2000 | CA2338173A1 Method for making coated gabapentine or pregabaline particles |
| 02/17/2000 | CA2338121A1 Amide derivatives useful as inhibitors of the production of cytokines |
| 02/17/2000 | CA2338035A1 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid |
| 02/17/2000 | CA2337963A1 Latency-active regulatory sequences of herpesviruses and latency-inactive herpesvirus for gene transfer |
| 02/17/2000 | CA2336523A1 Immunological herpes simplex virus antigens and methods for use thereof |
| 02/17/2000 | CA2335648A1 A novel g protein-coupled receptor protein and its dna |
| 02/17/2000 | CA2305406A1 Pharmaceutical compounds |
| 02/17/2000 | CA2305198A1 Solution for resuscitating multicellular organism cells and method for resuscitating multicellular organism cells by using the same |
| 02/17/2000 | CA2245202A1 Tumour localising photosensitising compounds |
| 02/16/2000 | EP0979870A1 Human Wnt-6 polypeptide |
| 02/16/2000 | EP0979869A1 Short oligonucleotides for the inhibition of VEGF expression |
| 02/16/2000 | EP0979822A1 Process for the preparation of 2-carbamoyl-pyridines |
| 02/16/2000 | EP0979817A1 Leukotriene a 4? hydrolaze inhibitors |